Kalvista Pharmaceuticals Inc (KALV)

Feb 21, 2025

Can This New Oral Drug Transform HAE Treatment? Key Clinical Data Revealed - StockTitan

Feb 21, 2025

Feb 20, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 5,104 Shares - MarketBeat

Feb 20, 2025

Feb 20, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 Shares - MarketBeat

Feb 20, 2025

Feb 20, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 8.7%What's Next? - MarketBeat

Feb 20, 2025

Feb 20, 2025

KalVista Pharmaceuticals chief medical officer sells $30,700 in stock By Investing.com - Investing.com Canada

Feb 20, 2025

Feb 19, 2025

KalVista Pharmaceuticals CEO sells $50,142 in stock - Investing.com India

Feb 19, 2025

Feb 19, 2025

KalVista Pharmaceuticals chief medical officer sells $30,700 in stock - Investing.com India

Feb 19, 2025

Feb 19, 2025

KalVista Pharmaceuticals chief development officer sells shares for $25,552 - Investing.com India

Feb 19, 2025

Feb 19, 2025

KalVista Pharmaceuticals CEO sells $50,142 in stock By Investing.com - Investing.com Nigeria

Feb 19, 2025

Feb 19, 2025

KalVista Pharmaceuticals chief development officer sells shares for $25,552 By Investing.com - Investing.com Nigeria

Feb 19, 2025

Feb 19, 2025

KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView

Feb 19, 2025

Feb 18, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - Defense World

Feb 18, 2025

Feb 18, 2025

Japan grants orphan drug status to HAE treatment - MSN

Feb 18, 2025

Feb 18, 2025

Venrock Healthcare Capital Par Purchases 100,000 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock - MarketBeat

Feb 18, 2025

Feb 17, 2025

(KALV) Investment Analysis - Stock Traders Daily

Feb 17, 2025

Feb 16, 2025

KalVista Pharmaceuticals sees $1.5m stock purchase by Venrock - MSN

Feb 16, 2025

Feb 15, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Acquires $37,812.18 in Stock - MarketBeat

Feb 15, 2025

Feb 14, 2025

KalVista Pharmaceuticals sees $967,144 in stock purchases by Venrock - MSN

Feb 14, 2025

Feb 12, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 73,649 Shares of Stock - MarketBeat

Feb 12, 2025

Feb 12, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Bought by SG Americas Securities LLC - Defense World

Feb 12, 2025

Feb 11, 2025

Hereditary Angioedema Market Expected to rise, 2034 | KalVista - openPR

Feb 11, 2025

Feb 10, 2025

KalVista Completes Study On Hereditary Disorder Treatment: Shares Dip - BW Healthcare World

Feb 10, 2025

Feb 10, 2025

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting - The Bakersfield Californian

Feb 10, 2025

Feb 10, 2025

KALV: Sebetralstat Shows 1.3-Hour Relief in HAE Attacks, New Clinical Data Reveals | KALV Stock News - StockTitan

Feb 10, 2025

Feb 08, 2025

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Venrock Healthcare Capital Par Purchases 43,707 Shares - MarketBeat

Feb 08, 2025

Feb 07, 2025

Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases 14,562 Shares of Stock - MarketBeat

Feb 07, 2025

Feb 07, 2025

(KALV) Investment Report - Stock Traders Daily

Feb 07, 2025

Feb 05, 2025

JMP reiterates Kalvista stock with $19 target, sees market growth - MSN

Feb 05, 2025

Feb 04, 2025

Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Target Price at $25.00 - MarketBeat

Feb 04, 2025

Feb 04, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Now Covered by JMP Securities - MarketBeat

Feb 04, 2025

Feb 04, 2025

Angioedema Pipeline 2024: Therapies Under Investigation, - openPR

Feb 04, 2025

Feb 04, 2025

KalVista Pharmaceutical's Major Talent Push: 261,000 Stock Options Awarded in Strategic Growth Move - StockTitan

Feb 04, 2025

Feb 04, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Feb 04, 2025

Feb 04, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Citizens Jmp to Strong-Buy Rating - MarketBeat

Feb 04, 2025

Feb 03, 2025

Sebetralstat up for approval in Japan as on-demand HAE treatment - Angioedema News Today

Feb 03, 2025

Feb 03, 2025

Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $25.00 - Defense World

Feb 03, 2025

Feb 03, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Earns Outperform Rating from Analysts at JMP Securities - Defense World

Feb 03, 2025

Feb 02, 2025

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Passes Above 50 Day Moving AverageHere's Why - MarketBeat

Feb 02, 2025

Feb 02, 2025

Citizens Jmp Upgrades KalVista Pharmaceuticals (NASDAQ:KALV) to Strong-Buy - Defense World

Feb 02, 2025

Feb 01, 2025

JMP Securities sets $19 target for Kalvista Pharmaceuticals stock - MSN

Feb 01, 2025

Feb 01, 2025

JPMorgan Chase & Co. Raises Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World

Feb 01, 2025

Feb 01, 2025

JMP Securities Initiates Coverage of KalVista Pharmaceuticals (KALV) with Market Outperform Recommendation - MSN

Feb 01, 2025

Jan 31, 2025

JMP reiterates Kalvista stock with $19 target, sees market growth By Investing.com - Investing.com Canada

Jan 31, 2025

Jan 31, 2025

JMP Securities sets $19 target for Kalvista Pharmaceuticals stock By Investing.com - Investing.com Canada

Jan 31, 2025

Jan 31, 2025

JMP Securities Initiates KalVista Pharmaceuticals at Market Outperform With $19 Price Target - Marketscreener.com

Jan 31, 2025